AUTHOR=Yu Lingfeng , Lanqing Gong , Huang Ziyu , Xin Xiaoyan , Minglin Liang , Fa-hui Lv , Zou Hongmei , Min Jie 

TITLE=T cell immunotherapy for cervical cancer: challenges and opportunities

JOURNAL=Frontiers in Immunology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1105265

DOI=10.3389/fimmu.2023.1105265

ISSN=1664-3224

ABSTRACT=<p>Cancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded <italic>in vitro</italic>, and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy.</p>